# Spine BioPharma

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/spine-biopharma

- Industry: Biotechnology
- Headquarters: New York, US
- Website: www.spinebiopharma.com
- Total disclosed funding: $18M
- Latest round: Series B (Mar 28, 2022)
- Investors on record: 4

## About

Based in New York, US, and founded in 2015, Spine BioPharma, LLC, aka Spine BioPharma operates as a provider of therapeutic solutions for spine diseases. In March 2022, Spine BioPharma, LLC raised USD 13 million in Series B funding from returning investors Cercano Management. As of 2022, the firm is led by its CEO, Marc Viscogliosi.

The company’s product portfolio includes SB-01 which is a therapeutic solution for degenerative disc treatment. The firm's solution has clinical advantages such as pain alleviation, function restoration, and disease progression avoidance.

The firm plans to use the March 2022 funding for business expansion through further development of SB-01 formerly referred to as Remedisc™.

## Funding rounds

- Series B, Mar 28, 2022, $13M — Viscogliosi Brothers, Pacira Pharmaceuticals, Inc., Cercano Management
- Series A, Mar 12, 2021, $5M — Vulcan, Viscogliosi Brothers

## Investors

- Vulcan (https://capitalatlas.ai/funds/vulcan) — Series A
- Viscogliosi Brothers (https://capitalatlas.ai/funds/viscogliosi-brothers) — Series A, Series B
- Pacira Pharmaceuticals, Inc. — Series B
- Cercano Management (https://capitalatlas.ai/funds/cercano-management) — Series B